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A common principle of all highly developed societies is the provision of at least basic health 
care services to each member of society by the public sector free of charge. As a result, in 
most industrialised countries, and notably in all Member States of the European Union, health 
care constitutes a significant share of public expenditure. At the present time, total 
expenditure on health care in the EU accounts for between 4 and 11% of GDP, out of which 
between 3 and 9% of GDP is financed from public sources
1. Moreover, as it accounts for 
between 10 and 18 % of total government spending
2, health care is therefore among the most 
significant items of social public expenditure. 
 
Public expenditure on health care has been growing over most of the second half of the 20th 
century, not only in absolute terms, but also in relation to the national income. This practically 
constant increase was a result of profound economic, institutional, social and technological 
changes which occurred all over the industrialised world. Such changes led to an increase in 
public awareness, expectations, and demand for health care on the one hand, and to 
improvements in capacity of both the medical industry and providers allowing them to offer 
better, faster and more reliable, albeit often more expensive, health care on the other hand.  
 
There are a large number of factors which affect health care expenditure but the complexity of 
their interaction makes it difficult to draw precise lines which would identify their individual 
impact on health care expenditure growth.  However, a number of econometric tools exist that 
can be used to make an approximate estimation of the relative impact of the respective 
variables on health care production and spending. This can be done on the basis of past 
observations but the main interest for policymakers, industry and the general public lies in the 
explanatory power of such an exercise and its usefulness in predicting future developments in 
the health care sector. Such is the purpose of the joint European Commission-Economic 
Policy Committee (EC-EPC) long-term projections of age-related items of social 
expenditure
3, which has been the inspiration and methodological basis for the analysis 
presented in this publication.  
 
Taking as a basis the fundamental methodology used to project public health care 
expenditure, including mainly demand-side factors, such as demographic structure, income 
and health status of the population, the paper proposes to expand the model into the supply 
side by adding a supplementary module assessing the future impact of technological progress 
on public health care spending. Following a thorough analysis of the literature it concludes 
that there are no scientifically reliable forecasts of the future developments in the medical 
                                                 
1 Health including acute health care and long-term nursing care. Figures for 2007. Source: Eurostat. 
2 Figures for 2005. Cyprus with only 6% of general government outlays spent on health care is the only EU 
Member State beyond the indicated range. Source: European health for all database (HFA-DB), World Health 
Organisation Regional Office for Europe. 
3 The final report on the long-term budgetary projections is presented in European Commission and Economic 
Policy Committee (2009), while details of the methodologies and underlying data are discussed in European 
Commission and Economic Policy Committee (2008).   technology. Consequently, the only feasible way to project future evolution of spending 
driven by technological factors seems to be an extrapolation of the past trends, with all the 
caution required, while interpreting and using the results in the future policy debate. 
 
The paper concentrates mainly on the impact of non-demographic factors, in particular on the 
impact of technology development on health care expenditure. Section 2 briefly summarizes 
the outcomes of the relevant literature on the main factors found to impact on health care 
expenditure. Section 3 presents the discussion of the available data and results of econometric 
specification of the interaction between a number of variables in determining health care 
spending. Section 4 describes how the results of that exercise are used to project the long-term 
impact of technological progress on health care expenditure, with the methodology based on 
the EC-EPC model. Finally, section 5 concludes with the possible interpretations of the results 
and the description of the caveats surrounding such types of exercises. 
 
2. Drivers of health care costs – overview of the literature 
 
Notwithstanding the huge effort invested in the analysis of health care expenditure 
development and its determinants, to-date neither theoretical analysis nor empirical studies 
have provided unanimous conclusions. Thus, despite the significant efforts, an analysis of 
aggregate health care expenditure is an ongoing research topic.  
 
As for all public goods, the analysis of factors driving changes in health care expenditure 
differs, necessarily, between the micro and macro level. The existence of a number of legal 
and institutional restrictions regulating the provision of health care goods and services to the 
population constrains the functioning and alters the outcome of the market mechanisms 
driving individual citizens' and companies' behaviour at a micro level. In the context of health 
care, the universal health insurance coverage present - at least for a number of basic 
treatments - in practically all EU Member States, has arguably the largest impact on the 
individual behaviour of agents. In particular, universal coverage and high subsidies 
considerably reduce the elasticity of demand for health care with respect to both prices and 
income. In such a situation, while health care utilisation and spending is generally only linked 
to an individual's wealth to a limited degree, the market failure phenomena (moral hazard, 
information asymmetry) may drive patients to demand and providers to "produce" more 
health care than is justified by the actual health status. Those mechanisms do not work at the 
aggregate national level where income elasticity tends to be high, depending on the ability of 
the society to afford the high quality health care provided to each individual. On the other 
hand, even in the countries with the highest income, elasticity of overall public demand is 
limited by the budgetary caps, as health care is still mainly financed from public, limited 
sources
4. In sum, the analysis of drivers behind the evolution in health care spending is far 
from straightforward and must clearly distinguish between the macro and micro level, and 
take account of a complex network of interactions between patients, providers and payers as 
well as the division between public and private sector. 
 
The general approach to health care expenditure dates back to the seminal analysis by 
Newhouse (1977 and 1992). Using a decomposition of the health care expenditure growth, he 
                                                 
4 It is difficult to assess price elasticity at the aggregate level, except for the price of health care relative to the 
prices in the other sectors of economy. In this sense prices in health care tend to increase faster than in the 
general economy due to the Baumol effect, described further. 
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expenditure to GDP ratio. The role of aggregate income, demographic structure, productivity 
differences across economic sectors and technological progress is discussed among others. In 
particular, Newhouse stresses the role of technological progress. The remaining factors are 
found to be possibly responsible for growth in health care expenditure, but their role appears 
to be rather limited.  
 
Following Newhouse's research, a number of studies provided a quantitative analysis of the 
health care expenditure drivers, concentrating either on separate factors or aiming at finding 
the interactions between them.    
 
2.1. Demographic structure 
 
An ageing population is the most obvious factor behind increasing health care expenditure 
over the recent decades. Constantly growing life expectancy together with permanently low 
fertility rates have resulted in the gradual evolution of the demographic structure of 
populations that began with the last baby-boom period in the 1950's and 1960's and is not 
expect to shift sharply over the next decades. The effect of those changes has been a gradual 
increase in the share of older people in the population and – more recently – relative 
shrinkage of the young cohorts. This evolution has had an obvious impact on the demand for 
health care. Although the use of health care depends ultimately on the health status and not 
the age of a person itself, elderly people use health care more often and more intensively than 
young cohorts. Thus, the relative increase in the proportion of the elderly population 
contributes to the increase in demand for and expenditure on health care. 
 
Whilst this intuitive relationship is supported by most researchers, its strength is controversial. 
Most econometric studies analysing the common impact of a series of factors attribute more 
importance to income, technology and institutional factors, agreeing that demographic change 
has a positive, though relatively minor impact on health care spending. Contributing to this 
stream, Oliveira Martins and de la Maisonneuve (2006) analysed the dynamics of health care 
expenditure by distinguishing between demographic and non-demographic factors. As the 
authors claim, the impact of demographic factors seemed to be quite weak while the impact of 
non-demographic factors prevailed over the last decades.  
 
The group of non-demographic factors is usually represented by income growth, relative-price 
movements in the supply of health services and, arguably most significant but at the same 




Most studies agree that the link between health care expenditure and the demographic 
structure is becoming weaker over time, as, despite generally improving health status, the 
consumption of health care keeps increasing. This phenomenon is due to the growing share of 
health care expenditure both in household budgets and in the public government spending 
which, in turn, is driven by the increasing awareness of the health status, growing public 
expectations on the level of health care provision guaranteed by the state and growing 
availability of new technologies allowing to tackle new, previously untreatable, diseases. 
While it is generally agreed that the growth in national income brings about the increase in 
health care spending, the strength of this relationship, or the value of income elasticity of 
demand, remains uncertain. As mentioned in the previous section, a different perspective must 
  3be taken when analysing the issue at individual and aggregate level. At the individual level, 
the existence of health insurance makes the demand for health care, to a large extent
5, 
independent of an individual's income, which means that demand is highly inelastic. At the 
aggregate level, the situation is different: health care spending depends mainly on the level 
and composition of government expenditure, which evolves in line with the wealth of society. 
Nonetheless, here again, existing studies have not managed to provide a clear estimate of the 
income elasticity coefficient. On one hand, cross-country comparisons may intuitively suggest 
that health care is a luxury good, especially in the countries where health care is not yet a 
universally available public good (for example, the growth in health expenditure in the south-
European countries in the 1960s and 1970s exceeded the rate of growth in more advanced 
economies of the EU, but also their own GDP growth rate). On the other hand, more recent 
time series data suggest the opposite, especially as universal provision of health care is a fact 
in most industrialised countries today (GDP growth can hardly be solely responsible for faster 
increase in health care expenditure). Econometric studies do not provide clear evidence for 
one or the other hypothesis, finding elasticity coefficients either greater or smaller than one
6. 
 
The reasons for such variability in results could be due either to the different data sources, or 
to methodological problems. The outcomes of the empirical research studies were deeply 
influenced by advances in modern econometric techniques, e.g. time series and panel data 
techniques. In other words, the use of new methods and techniques often changed the view on 
existing theories and its empirical validation. 
 
Early analyses of the health care expenditure focused mainly on the relationship between this 
variable and national income, e.g. Culyer (1990) and Hitiris and Posnett (1992). Although 
additional variables were proposed by theory, the empirical work did not verify their 
usefulness in predicting health care expenditure in general. Thus, the existence of a positive 
correlation between health care expenditure and aggregate income was the main and only 
robust conclusion at that time. As rather simple estimation techniques were applied in the 
above mentioned studies, the estimated parameters have been found to be potentially biased.
7 
In particular, the income elasticity was very often found to be higher than one, indicating that 
health care may have features of a luxury good (e.g. Newhouse, 1977). 
 
The progress in time series and panel data techniques, e.g. development of, in particular, unit 
root and cointegration techniques, has brought new insights when analysing health care 
expenditure development. A number of papers demonstrated that the results obtained and 
conclusions proposed at that time could have been flawed due to so-called spurious regression 
between variables analysed or omitted variable bias.  
 
Initially, the analysis of stationarity and cointegration was carried out in a country-by-country 
manner, i.e. the properties of each cross-section representative were studied separately. 
Several papers tested a degree of integration of particular variables, demonstrating that the 
variables, usually involved when analysing health care expenditure, are not stationary. As a 
consequence of non-stationarity in the time series, a battery of alternative cointegration tests 
were applied in order to assess if standard estimation techniques can be applied or further 
adjustment to variables and techniques are needed. Although the conclusions proposed are far 
from uniform, it seems that, based on the above mentioned studies, health care expenditure 
                                                 
5 At least for the basic treatments where public insurance covers all (or large part) of the fees.  
6 For an overview of econometric studies, together with estimated income elasticities, see Getzen (2000). 
7 See Dreger and Reimers (2005) or van Elk, Mot and Franses (2009) for a discussion on the possible omission 
variable bias in early studies. 
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(1994), Blomqvist and Carter (1996), Gerdtham and Lothgren (2000). 
 
As the concepts of stationarity and cointegration have only been practically introduced into 
the panel data framework in the course of the last decade, they have been used extensively in 
health care expenditure analysis in order to make use of the increased number of observations 
and degree of freedom of pooled data, see for example Okunade and Murthy (2002), Ariste 
and Carr (2002), Dreger and Reimers (2005), van Elk et al (2009) among others. Once again, 
no general conclusion has been proposed by the empirical research. Despite this fact, it seems 
that the bulk of analyses tend to claim that health care expenditure and aggregate income are 
integrated of degree one and cointegrated. 
 
The fact that health economists have still not agreed upon either main conclusions or methods 
has been confirmed recently, as Jewell et al (2003), Carrion-i-Silvestre (2005) and Clemente 
et al (2004) extended the analysis of health care expenditure and aggregate income by 
introducing structural breaks. The authors propose, and document, that health care 
expenditure are mainly affected by government decisions and other exogenous factors such as 
a business cycle position etc. Not surprisingly, after introducing several structural breaks, both 
health care expenditure and aggregate income are found to be stationary
8. 
 
2.3. Relative prices in the health care sector and Baumol effect 
 
As explained by Newhouse (1992), health care spending has grown faster than income, which 
indicates that the effects of technology and relative prices seem to play a significant role in 
upwards pressure on health-care expenditure.  
 
A possible explanation of the strong growth in the ratio of health care expenditure to GDP 
seems to be the so-called Baumol effect. In his study, Baumol (1976) distinguishes between 
two types of sectors depending on the level of labour productivity growth, i.e. high and low 
productivity sectors. In general, labour intensive sectors, such as health care, are characterised 
by a low labour productivity growth. As, in the long-run, nominal wages in both sectors are 
related, wages in the low productivity sector rise to the same extent as in the high productivity 
sector, which results in growing price differentials between the two. In addition, if demand for 
the low productivity sector good is inelastic, as in the case of health care, the ratio of 
expenditure on these goods to GDP increases over time. Following this argument, one can 
explain increasing health care expenditure to GDP over time. The difficulty consists in the 
lack of reliable sectoral estimates of labour productivity, but may be partially offset by 
decomposing the overall spending growth into increases in volume and price. Occurrence of 
strong increases in prices relative to the other sectors may be evidence of the productivity gap 
and thus existence of Baumol effect. However, focusing on the empirical evaluation of the 
Baumol effect, Newhouse (1992) questioned its role, arguing that it is very difficult to assess 
labour productivity growth in the health care sector and it is certainly not obvious that labour 
productivity within this sector must be lower compared to other high productivity sectors. On 
the other hand, Baumol's conjecture was empirically tested and found statistically significant 
only recently by Hartwig (2007) and Pomp and Vujic (2008). In particular, Hartwig (2007) 
suggests that development of health care expenditure in OECD countries over the past forty 
years is in line with Baumol's theory. Concerning policy recommendations, Hartwig (2007) 
seems to be sceptical about efforts to offset permanent growth in health care expenditure in 
                                                 
8 A comprehensive overview of aggregate health care related literature is provided for example by Hartwig 
(2007). 
  5the long-run. He suggests that, following Baumol's theory, only an increase in labour 
productivity in the health care sector can lead to stabilisation of health care expenditure to 
GDP ratio. 
 
2.4. Medical technology 
 
Medical technology is arguably the most important supply factor affecting the entire process 
of development, production, delivery and financing of health care. While precise estimates of 
its contribution to the improvement in longevity and health status are still lacking, recent 
studies tend to attach to it an ever more crucial role in the explanation of health expenditure. 
Technology, defined as ‘the drugs (pharmaceuticals and vaccines), medical equipment, 
health-care procedures, supportive systems, and the administrative systems that can tie all 
these disparate elements together’
9 are considered as the main driver of health care costs in 
today's developed societies. The first attempt to quantify the impact of technology is 
attributed to Newhouse (1992), who found that the bulk of health care expenditure growth in 
the industrialised countries can be attributed to technological growth
10. A great deal of further 
studies has supported Newhouse inference, see for example Okunade and Murthy (2002). 
Recently, Oliveira Martins and de la Maisonneuve (2005) pointed out that since, over the last 
decades, health care spending has grown faster than the aggregate income, the effects of 
technology and relative prices seem to significantly affect health care expenditure 
development. 
 
Given the lack of empirical data and a uniform methodology to quantify the impact of medical 
technology on health care costs, three general approaches have been used in practice to 
estimate the size of its effect
11. 
 
•  The residual approach is based on the assumption that technology is responsible for 
all changes not accounted for by the other quantifiable factors. In practice, the effect 
of demographic changes, changes in health status, prices and income is subtracted 
from total increase in expenditure and the remaining part (residual) is attributed to 
changes in technology. Such a method avoids the difficulty of specifying the direct 
measure of technological progress and covers all types of technology used in the 
process of health care provision. On the other hand, however, it provides only a rough, 
indirect and, often, overestimated measure of the effect of technological progress as 
the residual includes, apart from technology itself, a series of other not quantified 
factors, such as institutional setting, behaviour, environment, education, etc. The 
examples of the studies using residual approach include: Newhouse (1992), Peden and 
Freeland (1998), Oliveira Martins and de la Maisonneuve (2005) and the present 
study. 
 
•  The  proxy approach uses an alternative measure to proxy the total impact of 
technology. An existing indicator is then introduced into the equation explaining the 
health care spending, assuming its changes follow the evolution of technology. The 
examples include: Okunade and Murthy (2002), where total R&D spending is found to 
                                                 
9 OECD (1998), p. 9.  
10 Other quantifiable factors (insurance coverage, income per capita, demographic changes, supplier-induced 
demand, sectoral productivity gains) account for less than half of the growth in real medical expenditure).  
11 For an overview of existing methods see : Freeland et al. (1998), Pammolli et al. (2005) and Productivity 
Commission, Australian Government (2005). 
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where such a proxy is just time.     
 
•  Case studies analyse the effect of a specific technology on the cost of treating a 
particular medical condition. They can play an important role in the process of 
developing new drugs or technological applications, but their contribution to the 
analysis of overall health care costs is very limited. In this context, the most useful 
studies are those focusing on the most significant conditions (selected according to 
prevalence rate, contribution to overall mortality or disability, etc.), which can be 
extended to the wider spectrum of medical conditions. The examples of such studies 
include i.a. Cutler and McClellan (2001) where the costs and benefits of introducing a 
new technology were compared for five selected conditions, or Baker et al. (2003), 
where supply of ten selected technologies was compared to health care utilisation and 
spending. 
 
Although empirical evidence clearly points to the cost-increasing effect of new technologies, 
whether a particular technology increases or decreases costs depends on its impact on unit 
cost and the level of use or on whether the treatment complements or replaces the existing 
methods. Broadly speaking, if the expected outcome is to treat in a better, faster and more 
efficient way diseases and medical conditions that have already been treatable before, the new 
technology is likely to reduce the use of other (less efficient/more costly) services and overall 
unit cost without changing the scope of treated population and therefore reduce total cost per 
patient. If the new method supplements the existing instrumentation and its purpose is to 
expand the treatment into the conditions that have not been treatable previously due to 
scientific (the methods of treatment are simply unknown) or economic (the methods of 
treatment are known, but enormous costs make it unfeasible on a larger scale) reasons, it will 
probably have a cost-increasing effect. Obviously, this picture is a highly schematic one and a 
number of other economic and behavioural mechanisms can influence and alter the budgetary 
effect of the new technologies, contingent on the legal and institutional setting currently in 
place. For example, in case of fixed budgets payment mechanisms, more cost-efficient 
technologies can hardly reduce overall expenditure simply because the providers will carry 
out proportionately more treatments at a lower unit cost to fulfil the budget (rebound effect). 
On the other hand, extra savings may be expected if a decrease in the relative price of a given 
type of treatment (due to e.g. the introduction of a new technology) reduces the use of the 
other, more expensive, substitute types of care (substitution effect). 
 
Another classification (proposed by Thomas, 1975) of the new technologies brought to market 
follows their expected medical effect and allows to distinguish two general types. On the one 
hand, so-called 'halfway technologies' do not prevent or cure disease, but they simply treat the 
symptoms or, in extreme cases, aim at saving life while not improving health status. The use 
of such technologies leads to the extension of lifespan, but also to longer and more costly 
treatment. Thus in spite of obvious social and human gains, their financial impact is clearly 
negative. On the other hand, 'high technologies' offer prevention or complete cure, which 
typically decreases or eliminate the burden of disease and brings cost-efficient outcomes
12. 
According to Weisbrod (1991), most technologies brought to market in the second half of the 
twentieth century (with the exception of vaccines) represented 'halfway technologies'. 
However, fast development of biomedicine over the last decade may give way to the 
                                                 
12 Thomas specifies also the third group, 'nontechnologies' which are the procedures undertaken in case of 
diseases which are intractable or poorly understood.  
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allow for understanding origins of diseases and successfully prevent their advance.  
  
Although there are some reasons to be optimistic about the future development of cost-
reducing technologies, the currently prevalent consensus, confirmed by the quantitative 
analyses and combined with the argument on the existence of the Baumol effect, states that 
the cost-increasing effects of developing new technologies prevail and the overall impact on 
expenditure tends to be positive.  
 
Identification of the main factors behind the progress of medical technologies helps in 
understanding its budgetary effects. Creation and development of new technologies are driven 
by both demand and supply side forces. On the one hand, they are 'pulled' by consumer 
demand driven by disposable income and increasing expectations linked to the growing living 
standards. Demand for health care technology grows, as much as demand for health care in 
general, as the population becomes wealthier and more aware of the health care needs and 
new opportunities created by technological innovations. On the other hand, development of 
new technologies is 'pushed' on the supply side by science, researchers, medical industry and 
providers. Practically all participants of the market for medical goods and services have stake 
in the development and fast diffusion of new, often high cost technologies
13: the main users of 
technology, and thus customers for innovators, are not the patients themselves, but the 
hospitals and physicians; clinicians are often actively involved in the process of developing 
and assessing the medical technologies; hospital managers often find rapid adoption of new 
technologies rewarding in a competitive environment; public is strongly influenced by the 
news on the benefits of new technologies. 
 
The supply of new technologies depends also on the type of health insurance contracts and the 
rules regulating the relationships between insurers and providers. Whether the system is 
supportive for investments in technological progress depends mainly on the definition of 
health care goods and services covered by insurance. If (i) the system is retrospective and 
cost-based (the amount of reimbursement is not specified ex-ante by a contract between 
insurer and patient or provider) thus allowing payments for all incurred costs and (ii) benefits 
covered by the insurance are not precisely specified as a list of existing procedures and drugs, 
the R&D sector has incentives to develop new technologies, as it has the guarantee that its 
investment will pay back. If, on the contrary, the system is prospective and defines ex-ante the 
budgets for health providers and the list of benefits to be reimbursed, industry does not invest 
in the new technologies, knowing that they cannot be practically adopted before an often 
lengthy and costly process of registering them as the reimbursed benefits is finished. A strong 
factor affecting development of medical technology is also the level of competition between 
providers and insurers regulated by the law. On the one hand, the more freedom the patients 
have when choosing the provider and the type of treatment, the more incentives the providers 
have to differentiate their offer and supply the most effective and efficient treatments. On the 
other hand, in a highly standardised market for health insurance, any additional treatment or 
drug covered by an insurance contract may be a decisive factor encouraging patients to the 
sign it with the insurer offering the widest or most differentiated coverage. 
 
                                                 
13 See Rutten and Bonsel (1992). 
  82.5. Other factors  
 
Apart from the above-mentioned factors, a number of other variables have been tested for the 
impact on the health care expenditure. These included mainly institutional (e.g. share of 
publicly provided or financed health care, role of GP's as an independent entity and 
gatekeeper, density of physicians, etc.) and behavioural (e.g. alcohol and tobacco 
consumption) variables, but no clear evidence was found to support the hypothesis on the 
significant role of any individual factor.  
 
3. Assessing the impact of medical technology on health care 
spending 
 
3.1. Econometric model: detailed specification  
 
Following the literature we estimate health care expenditure developments introducing both 
demographic and non-demographic factors. As proposed by the literature, we estimate the 
impact of the above mentioned factors on health care expenditure for each European country 
covered by OECD health care statistics
14: 
 
t t t t t t trend BELOW OVER GDP HCE α α α α α ε + + + + + = 5 4 3 2 1 20 80
t i t i t i t i t i t i , , 5 , 4 , 3 , 2 1 , 20 80
.    
 (1) 
 
Afterwards we pool the data set and estimate the following model: 
 
trend BELOW OVER GDP HCE ε α α α α α + + + + + = .  
  (2) 
 
where HCE represents the logarithm of the real per capita health care expenditure in national 
currency units.
15 GDP represents the logarithm of the real per capita GDP in national 
currency unit, OVER80 and BELOW20 stand for the ratio of people over 80 and below 20 
years to the total population, trend is the determinis
16 tic trend.  
                                                
 
The variables used: GDP, HCE_TOT and HCE_PUB are easily accessible via the OECD 
Health database, but the development of variables characterising technological progress and 
relative-price movements are usually not at our disposal. In particular, reliable data on relative 
price developments for a sufficiently long time period is almost impossible to find. Thus, the 
impact of technological trend and relative price development on health expenditure is 
estimated by using only one aggregate non-demographic factor. The literature proposes that 
the development of this factor can be proxied by a deterministic trend term
17. However, such 
 
14 The sample covers 20 OECD members from Europe. Unfortunately, the majority of RAMS (the 12 recently 
acceded MSs) countries are not OECD members thus RAMS countries are under represented in the sample. 
Because of the membership in AWG, Norway was included in the EU15 group.  
15 Equation (1) and (2) were estimated separately for HCE being total health care expenditure (HCE_TOT) and 
public health care expenditure (HCE_PUB). Data can be downloaded from 
http://www.ecosante.org/index2.php?base=OCDE&langh=ENG&langs=ENG&sessionid= 
16 There are alternative possibilities for a variable which represents demographic factors. Usually ratio of people 
over 65 to total population or dependency ratio is applied. 
17 Still, there are some exceptions like Okunade and Murthy (2002) who confirmed a significant and stable long-
run relationship between per capita real health care expenditure, per capita real income and technological 
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technology growth and relative prices). 
  
When applying time series methods one needs to pay special attention to the existence of 
stochastic trends (non stationarity), the existence of cointegrating relationship and possible 
endogeneity among dependent and explanatory variables. 
 
3.2. Non stationarity (Unit roots) 
 
After Culyer (1990), Hitiris and Posnett (1992) and others claimed that there seems to be a 
strong relationship between HCE and aggregate income, Hansen and King (1994) pointed out 
that it is possible that the strong positive correlations observed between HCE and GDP in the 
previous studies were a result of non-stationarity in the respective time series, rather than 
evidence of an actual economic relationship. Hansen and King (1994) showed that two-thirds 
of the variables tested (HCE and GDP per capita in real terms) were found to be non-
stationary in levels and no country possessed a data set that was entirely stationary in levels. 
The non-stationarity of real per capita HCE and GDP was indicated also by Blomqvist and 
Carter (1996) and Gerdtham and Lothgren (2000). Using alternative unit root tests, 
MacDonald and Hopkins (2002), Okunade and Murthy (2002) among others, found strong 
evidence of unit roots in both GDP and HCE data when the data are considered as a panel.
18 
 
Applying augmented Dickey-Fuller unit root tests to our sample leads to the conclusion that 
the logarithm of real per capita health care expenditure and the log of real per capita GDP 
have a unit root, i.e. in most cases a Ho hypothesis of a unit root cannot be rejected. Still in 
some cases the test outcomes suggest that the two mentioned series could be stationary once a 
deterministic trend is introduced. When interpreting the results of Table 1 caution must be 
exercised since the power of this test is rather low in a small sample
19.  
 
In order to obtain more reliable evidence concerning stationarity of the analysed variables, 
country specific time series are pooled and alternative panel unit root tests are applied. First, 
the existence of a common unit root in all time series is tested following Levine, Lin and 
Chun and Breitung tests. Second, allowing for existence of individual-specific unit roots Im, 
Peseran, Shin and a panel version of Phillips Peron test are applied
20. Each time a constant 
and a deterministic trend enter the test equation. Based on the outcomes of all four tests, see 
Table 2, both HCE_TOT and HCE_PUB are rejected to be stationary at 10% significance 
level. Concerning stationarity of GDP, evidence is not actually clear; still assume the null 
hypothesis of GDP stationarity is in general rejected. 
 
Thus, following economic intuition and the outcomes of several studies we assume that 
HCE_TOT, HCE_PUB and GDP are (1).  
                                                                                                                                                          
change, proxied by total R&D expenditure. Albrecht, Neyt and Verbeke (2005) proxy the impact of new 
technologies on health care expenditure by the number of researchers. 
18 On the other hand, recently Carrion-i-Silvestre (2005) suggested that the panel data set of HCE is stationary 
after the structural breaks are introduced into the model. Since most of the breaks are associated with reforms 
aimed to extend the coverage and benefits of health care, this argument is in line with the fact that governments 
play a major role in the financing of HCE in most of the OECD countries, and therefore, it is a consequence of a 
strong correlation between HCE and GDP. 
19 Thus, due to a limited number of observations, the series could be claimed to be an I(1) process even if it is 
I(0) in fact. 
20 An overview of panel data unit root and cointegration tests is provided by Banerjee (1999). 
  10Table 1. Augmented Dickey-Fuller test
21 
HCE_TOT HCE_PUB GDP
AT 0.72 0.61 0.41
BE 0.21 NA 0.36
CZ 0.01 0.03 0.78
DK 0.83 0.09 0.03
FI 0.26 0.27 0.03
FR 0.46 0.29 0.35
DE 0.00 0.00 0.18
GR 0.17 0.02 0.42
HU 0.83 0.93 0.00
IE 0.82 0.67 0.84
IT 0.30 0.62 0.85
LU 0.40 0.28 0.41
NL 0.08 0.06 0.45
NO 0.32 0.02 0.38
PL 0.04 0.24 0.10
PT 0.00 0.24 0.12
SK 0.89 0.45 0.21
ES 0.26 0.01 0.09
SE 0.06 0.01 0.47
UK 0.60 0.90 0.75  
Note: The values represent p-values of the Ho that the series has a unit root. The Ho is rejected if the p-value is 
smaller than or equal to the significance level. If significance level is 0.1 than Ho is rejected when p-value<= 
0.1.  
 
Table 2. Panel unit root tests 
HCE_TOT HCE_PUB GDP
Common unit root test:
LLC 0.06 0.12 0.00
Breitung 0.23 0.31 0.47
Individual unit root test:
IPS 0.10 0.37 0.00
PP 0.90 0.62 0.04  
Note:  
Common unit root test: LLC - Levin, Lin, Chu; Breitung. 
Individual unit root test:  IPS - Im, Peseran, Shin; PP-Fisher Chi-square. 
The values represent p-values of the Ho that the series has a unit root. The Ho is rejected if the p-value is 





The problem of regressing non-stationarity variables disappears in case their linear 
combination is stationary. In such a situation, OLS estimates in levels are superconsistent.  
 
Hansen and King (1994) conclude that there is practically no evidence that the two series 
(HCE and GDP) are cointegrated for any country, i.e. that there is no long-run relationship 
between HCE and GDP. On the other hand, Blomqvist and Carter (1996) confirm the 
existence of a cointegration in the country-by-country case. The null hypothesis of no 
cointegration was rejected at the 5% level for 16 countries. In addition, after pooling country 
variables, the authors concluded that HCE and GDP are I(1) and are cointegrated around a 
linear trend.  
                                                 
21 Applying Phillips-Peron test does not change the results significantly. See table 9 in the Annex. 
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A similar conclusion, i.e. the existence of the long run equilibrium relationship between HCE 
and GDP, using panel cointegration tests was confirmed by Gerdtham U. G., Lothgren M. 
(2000), Dreger and Reimers (2005) or by Okunade and Murthy (2002).  
 
Using the Dickey-Fuller approach, on a country-by-country basis, in testing cointegration in 
our sample leads to the conclusion that health care expenditure and GDP per capita are not 
cointegrated in a number of case cases (see Table 3)
22. The presence of a cointegration 
relationship was tested for all countries even when both series are I(0) or one series is I(0) and 
the second one is I(1) or vice versa
23.  
 
A number of panel cointegration tests has been introduced recently, in order to provide more 
plausible evidence of cointegration relationship among variable
24. Table 4 provides outcomes 
of two tests proposed by Pedroni and by Kao. All these tests extend the Engle-Granger 
framework to tests involving panel data, i.e. the residual-based cointegration tests. 
 
The individual country-by-country tests do not provide clear evidence of the existence of the 
cointegration relationship between the variables for all countries, see Table 3. On the 
contrary, based on the panel cointegration tests in Table 4, the null hypothesis of no 
cointegration relationship can be rejected. As a consequence, taking into account our results 
and recently published studies we assume that HCE and GDP are cointegrated for all 
countries and decide to estimate the long-run relation between these variables using OLS. A 
full dynamic error correction model estimate, taking into account the adjustment mechanism 
over time, is not feasible given the lack of data.  
 
                                                 
22 When applying Johansen’s cointegration test the conclusions are almost the same. See Tab 10 in the Annex. 
23 See for example Muscatelli and Hurn (1992) who advocate this approach. It should be noted that it is not fully 
methodologically correct in this case. 
24 See Banerjee (1999) for an overview and discussion of existing panel cointegration tests. 





















UK 0.3 0.7  
Note: The values represent p-values of the Ho that the residual series has a unit root, i.e. that the variables 
(HCE, GDP and over_65) are not cointegrated. The Ho is rejected if the p-value is smaller than or equal to the 
significance level. If significance level is 0.1 than Ho is rejected when p-value<= 0.1.  
 
Table 4. Panel cointegration tests. 
HCE_TOT HCE_PUB
Pedroni
Panel ADF 0.03 0.00
Group ADF 0.03 0.00
Kao
0.00 0.00  
Note: The values represent p-values of the Ho that the the variables (HCE, GDP and over_65) are not 
cointegrated. The Ho is rejected if the p-value is smaller than or equal to the significance level. If significance 
level is 0.1 than Ho is rejected when p-value<= 0.1.  
 
3.4. Technology trend estimation 
 
Following Blomqvist and Carter (1996) and Ariste and Carr (2002), we extended the model 
by a linear time trend. Such a deterministic trend is expected to account for the impact of 
technological change on health care expenditure. The authors stress that their estimates of the 
deterministic trend coefficient are very imprecise and vary widely in magnitude between 
countries. However, their trend coefficient estimates suggest that HCE in the sample of 
countries tends to rise by as much as 2% per year even if income remains constant. Okunade 
and Murthy (2002) also confirm a significant and stable long-run relationship among HCE, 
GDP and technological change (this time proxied by total R&D expenditure). As suggested 
earlier, this can be taken as support for the growing consensus that the technology growth has 
been the most important determinant of the growth in the cost of health care in industrialized 
countries since the World War II. 
 
Table 5 presents the results when estimating equation (1) using OLS. The results should be 
interpreted with caution, especially for Recently Acceded Member States (RAMS) countries 
where the length of time series is extremely short. 
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Table 5. Single equation estimates 
HCE_TOT HCE_PUB HCE_TOT HCE_PUB
AT cons -12.76 ** -19.85 *** IT cons -11.78 -24.75 *
GDP 1.95 *** 2.65 *** GDP 1.80 * 2.95 *
ABOVE 80 -0.01 0.03 ABOVE 80 0.04 0.10
BELOW 20 0.02 0.03 BELOW 20 0.04 *** 0.10 ***
trend 0.01 0.00 trend 0.01 0.01
BE cons -20.80 *** LU cons 29.69 34.35 *
GDP 2.80 *** GDP -1.63 -1.93 *
ABOVE 80 0.18 ABOVE 80 -0.58 -0.62
BELOW 20 0.02 BELOW 20 -0.27 -0.34
trend -0.02 trend 0.10 *** 0.10 ***
CZ cons 16.00 12.91 NL cons 3.09 9.24 *
GDP -0.51 -0.35 GDP 0.31 -0.06
ABOVE 80 0.31 0.23 ABOVE 80 0.05 -0.44
BELOW 20 -0.06 -0.03 BELOW 20 0.01 * -0.05 **
trend 0.01 0.02 trend 0.02 ** 0.03
DK cons -0.82 -7.01 NO cons -15.18 *** -15.85 ***
GDP 0.57 * 0.93 ** GDP 2.00 *** 2.04 ***
ABOVE 80 0.39 *** 0.67 *** ABOVE 80 0.17 -0.01
BELOW 20 0.08 *** 0.13 *** BELOW 20 0.01 0.02
trend 0.00 -0.01 trend -0.02 -0.01
FI cons 3.40 * 3.31 PL cons 9.13 ** 7.89 *
GDP 0.49 *** 0.58 *** GDP -0.31 0.20
ABOVE 80 0.23 *** 0.26 *** ABOVE 80 -0.11 -0.10
BELOW 20 -0.05 *** -0.08 *** BELOW 20 -0.03 -0.08 ***
trend -0.01 -0.02 ** trend 0.05 *** -0.01
FR cons 4.75 5.65 PT cons -4.90 * -7.41
GDP 0.26 0.18 GDP 0.94 *** 1.28 ***
ABOVE 80 0.08 * 0.09 ABOVE 80 -0.32 ** -0.17
BELOW 20 -0.03 -0.04 BELOW 20 0.04 0.02
trend 0.02 0.02 trend 0.08 *** 0.05 **
DE cons -7.77 ** -7.41 * SK cons -22.08 -9.20
GDP 1.42 *** 1.36 *** GDP 0.54 1.44
ABOVE 80 0.05 0.05 ABOVE 80 0.19 0.11
BELOW 20 0.03 0.02 BELOW 20 0.86 0.05
trend 0.01 *** 0.01 ** trend 0.09 -0.01
GR cons 3.73 -4.43 * ES cons -9.30 *** -11.13 ***
GDP 0.32 1.04 *** GDP 1.44 *** 1.44 ***
ABOVE 80 0.00 -0.20 ABOVE 80 0.13 0.02
BELOW 20 -0.03 0.01 BELOW 20 0.05 *** 0.08 ***
trend 0.02 0.04 *** trend 0.02 *** 0.05 ***
HU cons -23.35 ** -26.50 ** SE cons -1.26 -0.03
GDP 1.95 *** 2.04 *** GDP 0.87 *** 0.71 *
ABOVE 80 -0.05 0.05 ABOVE 80 -0.65 *** -0.86 ***
BELOW 20 0.20 * 0.26 ** BELOW 20 0.03 ** 0.05 ***
trend 0.07 0.07 trend 0.07 *** 0.10 ***
IE cons -0.78 -1.68 UK cons 4.43 *** 5.34 **
GDP 0.98 ** 1.19 ** GDP -0.02 -0.26
ABOVE 80 -0.61 *** -0.86 *** ABOVE 80 0.07 0.10
BELOW 20 -0.02 -0.04 BELOW 20 0.04 *** 0.07 ***
trend 0.01 0.00 trend 0.04 *** 0.05 ***  
Note: *** statisticaly significant at 1% level, ** statisticaly signicicant at 5% level, * statisticaly significant at 
10% level 
 
  14The coefficient corresponding to GDP is interpreted as an elasticity of HCE with respect to 
GDP. The coefficient is to be positive and close to one. Estimates both below and above one 
can be supported on theoretical grounds. The coefficients corresponding to OVER80 and 
BELOW20 are interpreted as a semi-elasticity of HCE with respect to the development of 
demographic factors. In particular, OVER80 represents the impact of a higher ratio of older 
people in the population, while BELOW20 represents the effect of a higher ratio of young 
people in the population on health care spending. The empirical age profiles of health care 
spending reveal that in general the estimated coefficient related to OVER80 is expected to be 
positive and the coefficient related to BELOW20 is expected to be rather negative. The 
coefficient corresponding to trend can be interpreted as an average annual growth rate of HCE 
due to technology and other non-demographic factors. 
 
The estimated parameters are characterised by a quite high degree of dispersion.
25 In 
particular, the limited size of data sample leads to bizarre results in case of some countries as 
CZ, FR, LU, NL and UK. Taking into account only statistically significant results, we see that 
the average growth rate of per capita health care expenditure varies from 1 to 10% per annum.  
In an effort to obtain more robust results, we pooled the individual country data. In addition, 
to reflect the accession year to the EU, we split the data set in EU 15 and RAMS subgroups.
26 
 
Table 6. Pooled fixed effect regression estimates 
HCE_TOT HCE_PUB
EU cons 0.30 0.49
GDP 0.68 *** 0.65 ***
OVER 80 0.02 0.01
BELOW 20 -0.01 * -0.01 *
trend 0.02 *** 0.02 ***
EU_15 cons 0.69 0.76
GDP 0.65 *** 0.67 ***
OVER 80 -0.02 -0.08 **
BELOW 20 -0.01 ** -0.02 ***
trend 0.02 *** 0.02 ***
RAMS cons 3.04 * 5.88 ***
GDP 0.56 ** 0.50
OVER 80 0.16 *** 0.23 ***
BELOW 20 0.01 -0.03 **
trend 0.03 *** 0.03  
Note: *** statistically significant at 1% level, ** statistically significant at 5% level, * statistically significant at 
10% level 
 
As indicated in Table 6, for both total and public health care spending, the trend coefficient 
for EU15 countries is about 0.02, while in the case of RAMS countries, the coefficient is 
slightly higher (0.03). The difference in the level of the trend parameter between EU15 and 
RAMS countries can be explained by the lower level of health care standards in RAMS 
countries and their tendency to converge to EU level in the following years. 
 
The estimated value of income elasticity seems to be rather low (below 1). The surprisingly 
low value of the income elasticity can be a result of introducing mainly a time trend, the 
                                                 
25 The high degree of dispersion among individual country parameters was confirmed for example by Blomqvist 
and Carter (1996). 
26 In Table 4, EU15 group comprises of AT, BE, DK,FI, FR, DE, GR, IE, IT, LU, NL, NO, PT, ES, SE, UK and 
the group of RAMS covers only CZ, HU, PL and SK. 
  15OVER80 and BELOW20 variables, all growing remarkably in case of a majority of the 
countries over the period 1960-2006.  
 
As well as in the case of the country-by-country estimates the effect of demographic factors, 
approximated by OVER80 and BELOW20, is mixed. On the EU level, BELOW20 
coefficients are negative and statistically significant for both HCE_TOT and HCE_PUB, 
meaning that higher proportion of younger people in the society reduces the ratio of health 
care expenditure to GDP. On the contrary, the ratio of health care spending to GDP tends to 
increase as the proportion of older people in the population increases, still this relation was 
not found to be statistically significant. In case of EU_15 countries, the elasticities related to 
both variables representing demographic development (BELOW20 and ABOVE80) are 
negative, still statistically significant only for BELOW20 variable. On the contrary, the same 
elasticities were estimated to be positive in case of RAMS countries. This time ABOVE80 
variable was found to be statistically significant while BELOW20 was not. Our results are in 
line with conclusions by Oliveira Martins and de la Maisonneuve (2006) who claim the 
impact of demographic factors to be relatively weak while the impact of non-demographic 
factors prevailed over the last decades. 
 
As already mentioned, we introduce a linear trend into our calculations in order to proxy the 
effect of technology development on health care spending. This was a pragmatic choice as 
alternative variables describing the effect of the technology are difficult to find. 
Unfortunately, introducing a linear trend into our estimations affects the outcome of our 
estimates. In particular, the trend captures not only the impact of technology but also the 
impact of all other trending variables. In addition, introducing a deterministic trend into our 
model leads to a high degree of multicollinearity among variables and thus makes the 




4. Projecting the long-term budgetary impact of technological 
progress 
 
The econometric specification described in the previous section may serve as a basis for a 
tentative estimation of the future impact of technological progress on the public expenditure 
on health care. For this purpose, the standard macrosimulation model used in the European 
Commission and Economic Policy Committee long-term budgetary projections (European 
Commission and EPC, 2009) can be extended by a module which estimates the financial 
impact of technological progress. Obviously, given the large uncertainties surrounding future 
developments in medical technology such an exercise must be based on the strong assumption 





The European Commmission-Economic Policy Committee (EC-EPC) projections of public 
health care expenditure are based on the simple macrosimulation model based on the expected 
                                                 
27 In order to demonstrate the effect of the time trend on our regressions, we re-estimate the pooled fixed effect 
model when excluding the trend. The pooled fixed effect estimates excluding the time trend are presented in 
Table 11 in the Annex. As expected, after excluding a time trend the variables characterising demographic 
development turn to be statistically significant and of an expected sign. 
  16demographic and income changes affecting the overall demand for health care. According to 
this methodology, current public expenditure on health care is decomposed into per capita 
public spending and total population. For each year of the projections, total expenditure is 
calculated by multiplying population and per capita spending for each cohort and adding 
spending on all cohorts. To keep the spending constant in real terms (as percentage of GDP) 
per capita expenditure is assumed to grow in line with the evolution of GDP per capita, but in 
order to reflect the impact of national income the elasticity is assumed to exceed unity
28. Data 
on health care spending per capita have been reported by the EU Member States in the form 
of age-related expenditure profile disaggregated into genders and 5-year age cohorts. 
Population projections are the standard EUROPOP2008 projections established by Eurostat 
for each age and year up to 2060, while GDP growth projections have been prepared 
internally by the European Commission (DG ECFIN) in a close cooperation with the 




Extending this basic methodology to include the technology component consists of adding 
two additional and partially counterbalancing elements. On the one hand, an extra increase in 
per capita health care expenditure due to non-demographic drivers is added on top of the 
demographic and income effect. This is simply done by adding additional component, equal 
to the estimate of trend coefficient obtained from the econometric model, to the yearly rate of 
growth. On the other hand, the income effect is weakened by applying an income elasticity 
lower than unity (and equal to the estimate of the coefficient corresponding to GDP in the 
model specification). This effect is due to the fact that growth in national income is correlated 
with technological progress. In the basic projection methodology, in the absence of a separate 
estimate, high income elasticity coefficient incorporates significant part of the technology 
impact, which is not the case in the extended model, where adjusted income elasticity 
coefficient reflects only other, non-technological channels.  
 
As in any long-term projection, one should assume a convergence towards stationary steady 
state conditions, so the two discussed effects are assumed to gradually disappear over time. In 
practical terms, it is done by applying a simple convergence rule to both elements added to the 
projection model
30. However, the uncertainty on the speed of the adjustment process call for 
caution while interpreting the results. For that reason two separate variants have been 
constructed: in the first one full adjustment over entire projection period (2007-2060) is 
assumed, in the second one, the impact of technology is assumed to disappear after 30 years 
(by 2038).    
 
Although estimates are available for all countries covered by the analysis, their values differ 
considerably (see table 3), depending strongly on data availability and time series length. The 
latter is especially short for the recently acceded Member States, which limits the reliability of 
data and quality of results for that group of countries. In such case, it has been decided to use 
the panel data estimates based on the figures from all the countries included in the analysis. 
                                                 
28 Following own calculations and estimates of income elasticity found in empirical literature, the coefficient of 
elasticity used in the projections (AWG reference scenario) is assumed to be 1.1 in the base year (2007), 
converging to unity at the end of the projection period (2060).    
29 For the details of the methodologies and the underlying data, see: European Commission and Economic Policy 
Committee (2008). 
30 Additional component to the yearly increase starts in 2008 from the value resulting from the econometric 
specification (estimate of trend coefficient) and converges towards zero at the end of the projection period. The 
same applies to income elasticity which, in exchange, evolves from the obtained value (estimate of GDP 
coefficient) in 2008 to unity in 2060.   
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To conclude, given all the mentioned reservations, the extra impact of technology added on 
top of demographic and income effect amounts to about 2% per year in 2008 (first year of 
projection) and linearly converges towards zero by 2060. On the other hand, income elasticity 
coefficient defining the impact of GDP per capita changes on per capita health care 




Tables 7 and 8 show the results of the technology scenario using as input data the results of 
the econometric exercise presented in section 3.  
 
Table 7. Public health care spending as % of GDP – projections with the technology 
effect disappearing by 2060 







BE 7,6 8,1 9,7 12,9 14,1 6,5 5,3
B G4 , 74 , 85 , 46 , 87 , 52,8 2,0
CZ 6,2 6,5 7,7 10,7 12,4 6,2 4,0
DK 5,9 6,3 7,8 10,2 11,1 5,2 4,2
DE 7,4 7,9 9,7 13,3 14,6 7,2 5,4
E E4 , 95 , 05 , 77 , 48 , 63,6 2,4
IE 5,8 6,2 7,4 10,2 12,1 6,3 4,5
E L5 , 05 , 26 , 28 , 59 , 64,7 3,3
ES 5,5 5,9 7,0 9,8 11,2 5,6 4,0
FR 8,1 8,7 10,4 13,7 14,9 6,8 5,5
IT 5,9 6,3 7,5 10,2 11,1 5,3 4,2
C Y2 , 72 , 93 , 44 , 65 , 42,7 2,1
LV 3,5 3,5 3,9 5,1 5,7 2,3 0,9
LT 4,5 4,6 5,2 6,9 7,9 3,4 2,3
LU 5,8 6,1 7,1 9,6 10,6 4,8 3,6
HU 5,8 6,0 7,0 9,5 11,0 5,2 4,0
MT 4,7 5,2 6,7 10,4 12,8 8,1 4,8
N L4 , 85 , 16 , 48 , 69 , 34,5 3,5
AT 6,5 6,9 8,5 11,6 12,8 6,3 4,8
P L4 , 04 , 24 , 96 , 67 , 63,6 2,6
PT 7,2 7,7 9,3 12,4 14,3 7,1 5,2
R O3 , 53 , 64 , 15 , 66 , 73,2 1,8
SI 6,6 6,9 8,2 11,3 12,7 6,1 4,2
SK 5,0 5,1 6,1 8,5 10,0 5,1 2,8
FI 5,5 5,9 7,2 9,7 10,5 5,0 4,1
SE 7,2 7,6 9,0 11,5 12,6 5,4 4,6
UK 7,5 8,0 9,5 13,0 14,9 7,4 5,4
NO 5,6 6,3 8,0 11,5 13,3 7,6 6,3
EU27 6,7 7,1 8,5 11,6 13,0 6,3 4,8
EU15 6,9 7,3 8,8 11,9 13,3 6,4 4,9
EU12 4,7 4,8 5,6 7,6 8,9 4,2 2,9  
Source: European Commission, EPC 
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effect disappearing over 30 years 







BE 7,6 8,1 9,5 11,4 11,8 4,1 2,9
BG 4,7 4,8 5,3 6,2 6,4 1,7 1,0
CZ 6,2 6,5 7,7 9,6 10,4 4,2 2,0
DK 5,9 6,3 7,6 9,1 9,3 3,3 2,4
DE 7,4 7,9 9,5 11,7 12,1 4,7 3,0
EE 4,9 5,0 5,7 6,7 7,3 2,3 1,1
IE 5,8 6,2 7,2 9,1 10,1 4,2 2,5
EL 5,0 5,2 6,1 7,5 8,0 3,1 1,7
ES 5,5 5,9 6,9 8,7 9,3 3,8 2,1
FR 8,1 8,7 10,2 12,1 12,4 4,3 3,1
IT 5,9 6,3 7,4 9,0 9,2 3,4 2,3
CY 2,7 2,9 3,4 4,1 4,5 1,8 1,2
LV 3,5 3,5 3,9 4,6 4,8 1,4 0,0
LT 4,5 4,6 5,1 6,2 6,6 2,2 1,0
LU 5,8 6,1 7,0 8,5 8,9 3,1 1,9
HU 5,8 6,0 7,0 8,6 9,3 3,5 2,3
MT 4,7 5,1 6,6 9,3 10,7 6,0 2,7
NL 4,8 5,1 6,3 7,6 7,8 2,9 2,0
AT 6,5 6,9 8,3 10,3 10,7 4,2 2,6
PL 4,0 4,2 4,9 5,9 6,4 2,4 1,4
PT 7,2 7,7 9,1 11,1 12,1 4,9 3,0
RO 3,5 3,6 4,0 5,1 5,7 2,2 0,8
SI 6,6 6,9 8,1 10,1 10,6 4,0 2,1
SK 5,0 5,1 6,0 7,7 8,4 3,5 1,2
FI 5,5 5,8 7,1 8,6 8,8 3,3 2,4
SE 7,2 7,6 8,8 10,2 10,5 3,3 2,5
UK 7,5 8,0 9,4 11,6 12,5 5,0 3,0
NO 5,6 6,3 7,9 10,3 11,4 5,7 4,4
EU27 6,7 7,1 8,4 10,3 10,8 4,1 2,6
EU15 6,9 7,3 8,7 10,6 11,1 4,2 2,7
EU12 4,7 4,8 5,6 6,8 7,5 2,8 1,5  
Source: European Commission, EPC 
 
  19These results suggest a large increase in public health care expenditure over the projection 
period, exceeding significantly the outcomes of the scenarios which do not take account of the 
potential impact of medical technology on health care expenditure. The difference between 
the results of the presented scenarios and those of the AWG reference scenario
31 (presented in 
the last column of the tables) may be interpreted as the expected impact of technology (and 
other supply factors not related to the increase in the national income) on public health 
expenditure. Estimated at between 2.6 and 4.8% of GDP, it turns out to be significantly 
stronger than both the impact of demographic changes (approximate 1.7% of GDP
32) and 
extra effect of assumed higher income elasticity (0.4% of GDP
33). 
 
A total increase of between 4 and 6.5% of GDP (in absolute terms) shows that continuation of 
the past trends in the public spending on health care, even under a strong assumption of the 
extra effect fading away with time, almost doubles the current level of spending, which would 
put a significant pressure on the public finances and the probable need to implement measures 
limiting the spending increase which may – together with the other items of age-related social 




Progress in medical science and the development of new technologies strongly affect public 
expenditure on health care in most industrialised countries of the world. Although it is found 
to account for the highest share of spending growth, it is also the most difficult factor to 
quantify. Incomplete knowledge of the interactions between technology and other factors 
affecting health care expenditure constrains the reliability of past analysis. Uncertainty 
surrounding future developments limits the predictive ability of the extrapolation of the past 
trends into the future. However, bearing in mind the caveats of such an exercise, the analysis 
of the past developments can teach us a lot about the interactions between technology and 
other factors. Moreover, an attempt to project their joint impact on the overall and public 
health care expenditure can serve as a good approximation of future needs of financial 
resources and expected pressure on public finances coming from this constantly developing 
and growing sector of activity. 
 
A number of econometric tools were applied in order to estimate the expected impact of the 
technological progress on health care expenditures. Following the literature, a widely 
accepted specification of health care equation was used to estimate the annual trend growth 
rate of per capita health care expenditure for individual countries and pooled data. 
 
Taking into account the recent results provided by the economic literature, single OLS and 
pooled fixed effect regressions have been estimated. At individual country level a very wide 
dispersion in the trend growth rate of health-care expenditure was found. This may be due to 
                                                 
31 AWG reference scenario is the central scenario of the projections, illustrating expected combined impact of 
three main quantifiable factors: demographic change, evolution in the health status and the national income. For 
details, see European Commission and Economic Policy Committee (2009), p.137. 
32 Average EU27 increase (2007-2060) in public spending on health care in the pure demographic scenario. See 
European Commission and Economic Policy Committee (2009), p.130. 
33 Average EU27 difference in public spending on health care projected according to the income elasticity and 
pure demographic scenarios (2007-2060). In methodological terms, the difference between the two lies in the 
assumed income elasticity of demand (and spending) for health care. While in the pure demographic scenario it 
is unitary and constant, in the income elasticity scenario it converges linearly from 1.1 in 2007 to 1 in 2060. See 
European Commission and Economic Policy Committee (2009), p.134. 
  20other country-specific factors affecting health-care expenditure not captured in the estimation. 
Based on the results for pooled regressions, HCE trend growth rate was estimated at 2% and 
3% p.a. for the EU15 and RAMS countries respectively, which can be assigned mainly to 
technological progress, or to other non-demographic factors. At the same time, the regression 
analysis show an income elasticity lower than 1 (around 0.7 on average). These results may be 
considered to represent an underlying, average trend in health-care expenditure, estimates to 
be somewhat lower for the EU15 countries than for the RAMS countries.  
 
Applying the econometric estimates to the macrosimulation health care expenditure model, 
constructed by the European Commission and the Economic Policy Committee for the long-
term budgetary projections, allows for the calculation of the expected increase in health care 
expenditure over the next decades due to demographic, income and technological factors. 
Although the results of the exercise vary considerably according to the imposed assumptions, 
the effect of technology is generally found to considerably exceed both demographic and 
income effects. 
 
Nevertheless, these results should be interpreted with caution and a number of caveats should 
be borne in mind. First, the budgetary impact estimated in the presented models do not solely 
include the effect of future developments in the cost of 'medicines (pharmaceuticals and 
vaccines), medical equipment, health-care procedures, supportive systems, and the 
administrative systems that can tie all these disparate elements together’
34. In fact, it also 
reflects other non-demographic factors (except for national income), such as a number of cost 
drivers not covered by the presented specifications. These are non-quantifiable factors such as 
institutional and legal setting of health care system, developments in prices of health care 
goods and services etc.     
 
Second, given the lack of knowledge on the future developments in medical technology, 
projected evolution of health care expenditure is calculated using estimates based solely on 
the past observations. Given the strong assumption on simple extrapolation of past trends, the 
results may be considered as tentative given the very long projection horizon. 
 
Third, given the fact that the potential for technological development depends on the financial 
resources available for capital investment in the medical sector, the econometric analysis 
should clearly differentiate between the two sources of influence in order to avoid 
collinearity. Indeed, impact of technology may be partially reflected in the relation between 
health care spending and national income
35. 
 
In conclusion, as, together with public pensions, long-term care and other age-related 
spending items, health care contributes strongly to the expected pressures on the public 
spending in the years and decades to come, advances in medical technology and their impacts 
on health care expenditure raises obvious concerns in relation to the future evolution of social 
spending and sustainability of public finances. However, given its relevant contribution to 
growing longevity and improving health status, the role of technology is considered as 
positive and any attempt to contain its development must be based on objective cost-
effectiveness analysis. Such studies, comparing a new technology's costs and benefits should 
                                                 
34 Definition of medical technology, as quoted in OECD (1998). 
35 This is the case of the income elasticity scenario in the EC-EPC budgetary projections which, while projecting 
higher spending in countries with higher potential GDP growth, accounts to some extent for technological 
progress.  
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  24•  Annex 
 
Table 9. Philips-Perron unit root test 
HCE_TOT HCE_PUB GDP
AT 0.6 0.6 0.0
BE 0.2 NA 0.0
CZ 0.5 0.4 0.1
DK 0.8 0.4 0.0
FI 0.6 0.6 0.5
FR 0.5 0.3 0.4
DE 0.0 0.0 0.2
GR 0.2 0.0 0.2
HU 0.8 0.9 0.0
IE 0.7 0.9 0.9
IT 0.7 0.9 1.0
LU 0.7 0.6 0.7
NL 0.6 0.3 0.5
NO 0.4 0.1 0.6
PO 0.1 0.0 0.1
PT 0.0 0.2 0.4
SK 1.0 1.0 0.8
ES 0.1 0.0 0.5
SE 0.7 0.6 0.9
UK 0.5 0.8 0.4  
Note: The values represent p-values of the Ho that the series has a unit root. The Ho is rejected if the p-value is 
smaller than or equal to the significance level. If significance level is 0.1 than Ho is rejected when p-value<= 
0.1.  
 





















UK 0 0  
 
  25Table 11. Pooled fixed effect regression estimates when excluding deterministic trend 
HCE_TOT HCE_PUB
EU cons -4.09 *** -2.82 ***
GDP 1.13 *** 1.00 ***
OVER 80 0.11 *** 0.10 ***
BELOW 20 -0.01 * -0.01 **
trend
cons -4.78 *** -3.85 ***
EU_15 GDP 1.19 *** 1.14 ***
OVER 80 0.11 *** 0.04
BELOW 20 0.00 -0.02 ***
trend
cons 1.34 5.76 ***
GDP 0.68 *** 0.65 **
EU_10 OVER 80 0.21 *** 0.23 ***
BELOW 20 -0.03 *** -0.03 ***
trend  
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